Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

General Research Article

Positive Correlation between Circulating Fetuin-A and Severity of Coronary Artery Disease in Men

Author(s): Reza Afrisham, Maliheh Paknejad, Davod Ilbeigi, Sahar Sadegh-Nejadi, Sattar Gorgani-Firuzjaee* and Mahmoud Vahidi*

Volume 21 , Issue 2 , 2021

Published on: 01 June, 2020

Page: [338 - 344] Pages: 7

DOI: 10.2174/1871530320666200601164253

Price: $65

Abstract

Objective: Fetuin-A serves a dual function; its high levels are associated with metabolic syndrome, type 2 diabetes, obesity, insulin resistance, and nonalcoholic fatty liver disease, and on the other hand, it serves as a potent inhibitor of ectopic vascular calcification. Due to the opposing findings, the aim of the current study was to investigate serum fetuin-A levels in men with coronary artery disease (CAD).

Methods: In the case-control study, anthropometric and biochemical parameters were determined in 83 men (43 CAD patients and 40 control subjects). At last, the serum fetuin-A levels were measured using the fetuin-A human enzyme-linked immunosorbent assay (ELISA) kit.

Results: A significant difference was detected among the two groups for triglyceride and cholesterol levels (P=0.003 and P=0.002, respectively). The mean fetuin-A levels were determined 230.57 ± 63.76 and 286.35 ± 64.07 μg/ml for the control group and the CAD patients, respectively (P<0.001). Fetuin- A was significantly correlated to the severity of CAD (r 0.393, P<0.001) and associated with the risk of CAD in subjects (OR [CI] = 1. 144 [1.060-1. 235]; p = 0.001). A cut-off value of 237.4 μg/ml had good sensitivity (76.7%) and specificity (65.0%) for differentiating between two groups [area under curve (AUC) = 0.732 (CI=0.621-0.842); p < 0.001].

Conclusion: Our results indicated that fetuin-A levels were positively correlated to the severity of CAD. The findings suggest that there is a possible link between pathogenic mechanisms of atherosclerosis and fetuin-A; however, more investigations are needed in this regard.

Keywords: Fetuin-A, men, coronary artery disease, biomarker, case-control, Iran.

Graphical Abstract
[1]
Chen, X.; Zhang, Y.; Chen, Q.; Li, Q.; Li, Y.; Ling, W. Lower plasma fetuin-A levels are associated with a higher mortality risk in patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 2017, 37(11), 2213-2219.
[http://dx.doi.org/10.1161/ATVBAHA.117.309700]
[2]
Abubakar, I.; Tillmann, T.; Banerjee, A. GBD 2013 Mortality and causes of death collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet, 2015, 385(9963), 117-171.
[http://dx.doi.org/10.1016/S0140-6736(14)61682-2] [PMID: 25530442]
[3]
Khot, U.N.; Khot, M.B.; Bajzer, C.T.; Sapp, S.K.; Ohman, E.M.; Brener, S.J.; Ellis, S.G.; Lincoff, A.M.; Topol, E.J. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA, 2003, 290(7), 898-904.
[http://dx.doi.org/10.1001/jama.290.7.898] [PMID: 12928466]
[4]
Arad, Y.; Goodman, K.J.; Roth, M.; Newstein, D.; Guerci, A.D. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J. Am. Coll. Cardiol., 2005, 46(1), 158-165.
[http://dx.doi.org/10.1016/j.jacc.2005.02.088] [PMID: 15992651]
[5]
Vliegenthart, R.; Oudkerk, M.; Hofman, A.; Oei, H-H.S.; van Dijck, W.; van Rooij, F.J.; Witteman, J.C. Coronary calcification improves cardiovascular risk prediction in the elderly. Circulation, 2005, 112(4), 572-577.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.104.488916] [PMID: 16009800]
[6]
Iroz, A.; Couty, J-P.; Postic, C. Hepatokines: unlocking the multi-organ network in metabolic diseases. Diabetologia, 2015, 58(8), 1699-1703.
[http://dx.doi.org/10.1007/s00125-015-3634-4] [PMID: 26032022]
[7]
Stefan, N.; Häring, H-U. The role of hepatokines in metabolism. Nat. Rev. Endocrinol., 2013, 9(3), 144-152.
[http://dx.doi.org/10.1038/nrendo.2012.258] [PMID: 23337953]
[8]
Gejyo, F.; Schmid, K. Purification and characterization of the two forms of human plasma α 2HS-glycoprotein. Biochim. Biophys. Acta, 1981, 671(1), 78-84.
[http://dx.doi.org/10.1016/0005-2795(81)90096-9] [PMID: 6796128]
[9]
Zhao, Z-W.; Lin, C-G.; Wu, L-Z.; Luo, Y-K.; Fan, L.; Dong, X.F.; Zheng, H. Serum fetuin-A levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes. Biomarkers, 2013, 18(2), 160-164.
[http://dx.doi.org/10.3109/1354750X.2012.762806] [PMID: 23410047]
[10]
Mukhopadhyay, S.; Mondal, S.A.; Kumar, M.; Dutta, D. Proinflammatory and antiinflammatory attributes of fetuin-a: a novel hepatokine modulating cardiovascular and glycemic outcomes in metabolic syndrome. Endocr. Pract., 2014, 20(12), 1345-1351.
[PMID: 25370330]
[11]
Li, W.; Zhu, S.; Li, J.; Huang, Y.; Zhou, R.; Fan, X.; Yang, H.; Gong, X.; Eissa, N.T.; Jahnen-Dechent, W.; Wang, P.; Tracey, K.J.; Sama, A.E.; Wang, H. A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PLoS One, 2011, 6(2)e16945
[http://dx.doi.org/10.1371/journal.pone.0016945] [PMID: 21347455]
[12]
Nascimbeni, F.; Romagnoli, D.; Ballestri, S.; Baldelli, E.; Lugari, S.; Sirotti, V.; Giampaoli, V.; Lonardo, A. Do nonalcoholic fatty liver disease and fetuin-A play different roles in symptomatic coronary artery disease and peripheral arterial disease? Diseases, 2018, 6(1), 17.
[http://dx.doi.org/10.3390/diseases6010017] [PMID: 29462898]
[13]
Ix, J.H.; Wassel, C.L.; Kanaya, A.M.; Vittinghoff, E.; Johnson, K.C.; Koster, A.; Cauley, J.A.; Harris, T.B.; Cummings, S.R.; Shlipak, M.G. Health ABC study. Fetuin-A and incident diabetes mellitus in older persons. JAMA, 2008, 300(2), 182-188.
[http://dx.doi.org/10.1001/jama.300.2.182] [PMID: 18612115]
[14]
Stefan, N.; Hennige, A.M.; Staiger, H.; Machann, J.; Schick, F.; Kröber, S.M.; Machicao, F.; Fritsche, A.; Häring, H.U. α2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care, 2006, 29(4), 853-857.
[http://dx.doi.org/10.2337/diacare.29.04.06.dc05-1938] [PMID: 16567827]
[15]
Ix, J.H.; Shlipak, M.G.; Brandenburg, V.M.; Ali, S.; Ketteler, M.; Whooley, M.A. Association between human fetuin-A and the metabolic syndrome: data from the heart and soul study. Circulation, 2006, 113(14), 1760-1767.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.105.588723] [PMID: 16567568]
[16]
Stefan, N.; Fritsche, A.; Weikert, C.; Boeing, H.; Joost, H-G.; Häring, H-U.; Schulze, M.B. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes, 2008, 57(10), 2762-2767.
[http://dx.doi.org/10.2337/db08-0538] [PMID: 18633113]
[17]
Reinehr, T.; Roth, C.L. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J. Clin. Endocrinol. Metab., 2008, 93(11), 4479-4485.
[http://dx.doi.org/10.1210/jc.2008-1505] [PMID: 18728159]
[18]
Weikert, C.; Stefan, N.; Schulze, M.B.; Pischon, T.; Berger, K.; Joost, H-G.; Häring, H.U.; Boeing, H.; Fritsche, A. Plasma fetuin-A levels and the risk of myocardial infarction and ischemic stroke. Circulation, 2008, 118(24), 2555-2562.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.814418] [PMID: 19029462]
[19]
Mori, K.; Emoto, M.; Araki, T.; Yokoyama, H.; Teramura, M.; Lee, E.; Motoyama, K.; Koyama, H.; Shoji, T.; Inaba, M.; Nishizawa, Y. Association of serum fetuin-A with carotid arterial stiffness. Clin. Endocrinol. (Oxf.), 2007, 66(2), 246-250.
[http://dx.doi.org/10.1111/j.1365-2265.2006.02716.x] [PMID: 17223995]
[20]
Mori, K.; Ikari, Y.; Jono, S.; Emoto, M.; Shioi, A.; Koyama, H.; Shoji, T.; Ishimura, E.; Inaba, M.; Hara, K.; Nishizawa, Y. Fetuin-A is associated with calcified coronary artery disease. Coron. Artery Dis., 2010, 21(5), 281-285.
[http://dx.doi.org/10.1097/MCA.0b013e32832fe5d5] [PMID: 20436350]
[21]
Ix, J.H.; Barrett-Connor, E.; Wassel, C.L.; Cummins, K.; Bergstrom, J.; Daniels, L.B.; Laughlin, G.A. The associations of fetuin-A with subclinical cardiovascular disease in community-dwelling persons: the Rancho Bernardo study. J. Am. Coll. Cardiol., 2011, 58(23), 2372-2379.
[http://dx.doi.org/10.1016/j.jacc.2011.08.035] [PMID: 22115642]
[22]
Ix, J.H.; Katz, R.; De Boer, I.H.; Kestenbaum, B.R.; Peralta, C.A.; Jenny, N.S. Fetuin-A is inversely associated with coronary artery calcification in community-living persons: the multi-ethnic study of atherosclerosis. Clin. Chem., 2012, 58(5), 887-895.
[http://dx.doi.org/10.1373/clinchem.2011.177725] [PMID: 22377528]
[23]
Bilgir, O.; Kebapcilar, L.; Bilgir, F.; Bozkaya, G.; Yildiz, Y.; Pinar, P.; Tastan, A. Decreased serum fetuin-A levels are associated with coronary artery diseases. Intern. Med., 2010, 49(13), 1281-1285.
[http://dx.doi.org/10.2169/internalmedicine.49.3223] [PMID: 20606360]
[24]
Muendlein, A.; Stark, N.; Rein, P.; Saely, C.H.; Geller-Rhomberg, S.; Geiger, K.; Vonbank, A.; Drexel, H. Are AHSG polymorphisms directly associated with coronary atherosclerosis? Clin. Chim. Acta, 2012, 413(1-2), 287-290.
[http://dx.doi.org/10.1016/j.cca.2011.10.008] [PMID: 22024217]
[25]
Akin, F.; Celik, O.; Ayca, B.; Altun, I.; Diker, V.O.; Bıyık, I.; Siriopol, D.; Covic, A.; Kanbay, M. Associations of fibroblast growth factor 23 and fetuin-A with coronary plaque burden and plaque composition in young adults. J. Investig. Med., 2015, 63(4), 613-619.
[http://dx.doi.org/10.1097/JIM.0000000000000153] [PMID: 25679296]
[26]
Akin, F.; Celik, O.; Altun, I.; Ayca, B.; Diker, V.O.; Satılmıs, S.; Sahin, C. Relationship of fibroblast growth factor 23 and fetuin-A to coronary atherosclerosis. J. Diabetes Complications, 2015, 29(4), 550-555.
[http://dx.doi.org/10.1016/j.jdiacomp.2015.02.013] [PMID: 25772252]
[27]
Rittig, K.; Thamer, C.; Haupt, A.; Machann, J.; Peter, A.; Balletshofer, B.; Fritsche, A.; Haring, H.U.; Stefan, N. High plasma fetuin-A is associated with increased carotid intima-media thickness in a middle-aged population. Atherosclerosis, 2009, 207(2), 341-342.
[http://dx.doi.org/10.1016/j.atherosclerosis.2009.05.018] [PMID: 19615685]
[28]
Chen, X.; Zhang, Y.; Chen, Q.; Li, Q.; Li, Y.; Ling, W. Lower plasma fetuin-A levels are associated with a higher mortality risk in patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 2017, 37(11), 2213-2219.
[http://dx.doi.org/10.1161/ATVBAHA.117.309700] [PMID: 28912366]
[29]
Naito, C.; Hashimoto, M.; Watanabe, K.; Shirai, R.; Takahashi, Y.; Kojima, M.; Watanabe, R.; Sato, K.; Iso, Y.; Matsuyama, T.A.; Suzuki, H.; Ishibashi-Ueda, H.; Watanabe, T. Facilitatory effects of fetuin-A on atherosclerosis. Atherosclerosis, 2016, 246, 344-351.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.01.037] [PMID: 26828753]
[30]
Pal, D.; Dasgupta, S.; Kundu, R.; Maitra, S.; Das, G.; Mukhopadhyay, S.; Ray, S.; Majumdar, S.S.; Bhattacharya, S. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat. Med., 2012, 18(8), 1279-1285.
[http://dx.doi.org/10.1038/nm.2851] [PMID: 22842477]
[31]
Ormazabal, V.; Nair, S.; Elfeky, O.; Aguayo, C.; Salomon, C.; Zuñiga, F.A. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc. Diabetol., 2018, 17(1), 122.
[http://dx.doi.org/10.1186/s12933-018-0762-4] [PMID: 30170598]
[32]
Malin, S.K.; del Rincon, J.P.; Huang, H.; Kirwan, J.P. Exercise-induced lowering of fetuin-A may increase hepatic insulin sensitivity. Med. Sci. Sports Exerc., 2014, 46(11), 2085-2090.
[http://dx.doi.org/10.1249/MSS.0000000000000338] [PMID: 24637346]
[33]
Yang, S.J.; Hong, H.C.; Choi, H.Y.; Yoo, H.J.; Cho, G.J.; Hwang, T.G.; Baik, S.H.; Choi, D.S.; Kim, S.M.; Choi, K.M. Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women. Clin. Endocrinol. (Oxf.), 2011, 75(4), 464-469.
[http://dx.doi.org/10.1111/j.1365-2265.2011.04078.x] [PMID: 21521346]
[34]
Kadoglou, N.P.; Kottas, G.; Lampropoulos, S.; Vitta, I.; Liapis, C.D. Serum levels of fetuin-A, osteoprotegerin and osteopontin in patients with coronary artery disease: effects of statin (HMGCoA-reductase inhibitor) therapy. Clin. Drug Investig., 2014, 34(3), 165-171.
[http://dx.doi.org/10.1007/s40261-013-0157-y] [PMID: 24307429]
[35]
Jung, T.W.; Youn, B-S.; Choi, H.Y.; Lee, S.Y.; Hong, H.C.; Yang, S.J.; Yoo, H.J.; Kim, B.H.; Baik, S.H.; Choi, K.M. Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of the hepatokine fetuin-A. Biochem. Pharmacol., 2013, 86(7), 960-969.
[http://dx.doi.org/10.1016/j.bcp.2013.07.034] [PMID: 23948064]
[36]
Gielen, S.; Laughlin, M.H.; O’Conner, C.; Duncker, D.J. Exercise training in patients with heart disease: review of beneficial effects and clinical recommendations. Prog. Cardiovasc. Dis., 2015, 57(4), 347-355.
[http://dx.doi.org/10.1016/j.pcad.2014.10.001] [PMID: 25459973]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy